275 related articles for article (PubMed ID: 34053179)
41. Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment.
Zhou C; Zhang Y; Yan R; Huang L; Mellor AL; Yang Y; Chen X; Wei W; Wu X; Yu L; Liang L; Zhang D; Wu S; Wang W
Cell Death Differ; 2021 Feb; 28(2):715-729. PubMed ID: 32929219
[TBL] [Abstract][Full Text] [Related]
42. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
43. Prognostic impact of indoleamine 2,3-dioxygenase 1
Economopoulou P; Kladi-Skandali A; Strati A; Koytsodontis G; Kirodimos E; Giotakis E; Maragoudakis P; Gagari E; Maratou E; Dimitriadis G; Kotsantis I; Vagia E; Anastasiou M; Gkotzamanidou M; Kavourakis G; Lianidou E; Psyrri A
ESMO Open; 2020 May; 5(3):e000646. PubMed ID: 32414944
[TBL] [Abstract][Full Text] [Related]
44. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.
Seeber A; Klinglmair G; Fritz J; Steinkohl F; Zimmer KC; Aigner F; Horninger W; Gastl G; Zelger B; Brunner A; Pichler R
Cancer Sci; 2018 May; 109(5):1583-1591. PubMed ID: 29498788
[TBL] [Abstract][Full Text] [Related]
45. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
46. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Mitra D; Horick NK; Brackett DG; Mouw KW; Hornick JL; Ferrone S; Hong TS; Mamon H; Clark JW; Parikh AR; Allen JN; Ryan DP; Ting DT; Deshpande V; Wo JY
Oncologist; 2019 Jun; 24(6):e275-e283. PubMed ID: 30755500
[TBL] [Abstract][Full Text] [Related]
47. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Hacking S; Chavarria H; Jin C; Perry A; Nasim M
Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.
Takamatsu M; Hirata A; Ohtaki H; Hoshi M; Ando T; Ito H; Hatano Y; Tomita H; Kuno T; Saito K; Seishima M; Hara A
Cancer Sci; 2015 Aug; 106(8):1008-15. PubMed ID: 26033215
[TBL] [Abstract][Full Text] [Related]
49. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients.
Jia Y; Wang H; Wang Y; Wang T; Wang M; Ma M; Duan Y; Meng X; Liu L
Int J Cancer; 2015 Sep; 137(5):1095-106. PubMed ID: 25683635
[TBL] [Abstract][Full Text] [Related]
50. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
51. High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.
Wei L; Zhu S; Li M; Li F; Wei F; Liu J; Ren X
Front Immunol; 2018; 9():724. PubMed ID: 29719533
[TBL] [Abstract][Full Text] [Related]
52. In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients.
Al-Samadi A; Poor B; Tuomainen K; Liu V; Hyytiäinen A; Suleymanova I; Mesimaki K; Wilkman T; Mäkitie A; Saavalainen P; Salo T
Exp Cell Res; 2019 Oct; 383(2):111508. PubMed ID: 31356815
[TBL] [Abstract][Full Text] [Related]
53. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
54. Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy.
Guo Y; Liu Y; Wu W; Ling D; Zhang Q; Zhao P; Hu X
Biomaterials; 2021 Sep; 276():121018. PubMed ID: 34284200
[TBL] [Abstract][Full Text] [Related]
55. Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy.
Yang P; Zhang J
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509627
[TBL] [Abstract][Full Text] [Related]
56. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():791621. PubMed ID: 35003112
[TBL] [Abstract][Full Text] [Related]
57. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H; Mediavilla-Varela M; Antonia S
Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
[TBL] [Abstract][Full Text] [Related]
58. High Indoleamine 2,3-Dioxygenase Expression along with Low Bridging Integrator-1 Expression in Hepatocellular Carcinoma Patients.
Asghar K; Rana IA; Abubakar M; Hasham K; Tahseen M; Bilal S; Mehmood S; Farooq A; Siddique K; Loya A
Asian Pac J Cancer Prev; 2023 May; 24(5):1591-1600. PubMed ID: 37247278
[TBL] [Abstract][Full Text] [Related]
59. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
Zhu MMT; Dancsok AR; Nielsen TO
Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394
[TBL] [Abstract][Full Text] [Related]
60. IDO1 correlates with the immune landscape of head and neck squamous cell carcinoma: a study based on bioinformatics analyses.
Gkountana GV; Wang L; Giacomini M; Hyytiäinen A; Juurikka K; Salo T; Al-Samadi A
Front Oral Health; 2024; 5():1335648. PubMed ID: 38736462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
